Ra Pharmaceuticals, Inc. (RARX) financial statements (2021 and earlier)

Company profile

Business Address 87 CAMBRIDGE PARK DRIVE
CAMBRIDGE, MA 02140
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments26521070118
Cash and cash equivalents26521070118
Other undisclosed current assets10322
Total current assets:27521273120
Noncurrent Assets
Property, plant and equipment5566
Intangible assets, net (including goodwill)0000
Goodwill 000
Intangible assets, net (excluding goodwill)0000
Restricted cash and investments1111
Other undisclosed noncurrent assets3   
Total noncurrent assets:9777
TOTAL ASSETS:28421980127
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities171086
Accounts payable2343
Accrued liabilities15643
Deferred revenue and credits000
Other undisclosed current liabilities2   
Total current liabilities:191097
Noncurrent Liabilities
Liabilities, other than long-term debt 223
Deferred revenue and credits223
Other undisclosed noncurrent liabilities3000
Total noncurrent liabilities:3223
Total liabilities:22121110
Stockholders' equity
Stockholders' equity attributable to parent26220769117
Common stock0000
Additional paid in capital553395192186
Accumulated deficit(291)(188)(123)(69)
Total stockholders' equity:26220769117
TOTAL LIABILITIES AND EQUITY:28421980127

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net investment income4110
Gross profit:4315
Operating expenses(110)(69)(55)(33)
Other undisclosed operating loss(1) (1) 
Operating loss:(107)(66)(55)(28)
Nonoperating income (expense)411(1)
Other nonoperating expense(0)(0)(0)(1)
Loss from continuing operations before income taxes:(103)(65)(54)(29)
Income tax benefit 000
Net loss available to common stockholders, diluted:(103)(65)(54)(29)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(103)(65)(54)(29)
Comprehensive loss, net of tax, attributable to parent:(103)(65)(54)(29)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: